Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With Azacytidine or DA Regimen in Prevention the Relapse of Consecutive MRD Positive AML Patients
NCT05361057Phase 2Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Relapse-Free Survival at 6 months. Started Jun 2022; status: terminated.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05361057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361057.